DOCSLIB.ORG

Hemolytic Anemia and the Reactive Sulfhydryl Groups of the Erythrocyte Membrane

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hemolytic Anemia and the Reactive Sulfhydryl Groups of the Erythrocyte Membrane HEMOLYTIC ANEMIA AND THE REACTIVE SULFHYDRYL GROUPS OF THE ERYTHROCYTE MEMBRANE by Erwin Peter GABOR, M.D., C.M. A thesis presented to the Faculty of Graduate Studies and Research ~n partial fulfillment of the requirements for 1 the degree of Master of Science in Experimental Medicine. McGill University Clinic and Royal Victoria Hospital, Montreal, Quebec. April, 1964. HEMOLITIC ANEMIA AND THE REACTIVE SULFHYDR!L GROUPS OF THE ER'YTHROCITE MEMBRANE by Erwin Peter Gabor ( Abstract ) Membrane sul.fhydryl ( SH) groups have been reported to be important for the maintenance of red cell integrity E, ~ ( Jacob and Jandl, 1962 ). A technique has been developed for the determination of reactive membrane sulfhydryl content in intact erythrocytes, utilizing sub­ hemolytic concentrations of p-chloromercuribenzoate (PMB). The erythrocyte membrane of 52 healthy subjects contained 2.50 - 2.85 x lo-16 moles of reactive SH groups ( mean 2.50 ·~ 0.20 ) per erythrocyte, when determined by this method. A 27-56% reduction of erythrocyte membrane SH content was observed in various conditions characterized by accelerated red cell destruction, including glucose- 6-phosphate dehydrogenase ( G6PD ) deficiency, drug-induced, auto- immune and other acquired hemolytic anemias and congenital spherocytosis. Normal membrane sulfhydryl content was found in iron deficiency anemia, pernicious anemia in relapse, and in other miscellaneous hematological conditions. Inhibition of membrane SH groups with PMB caused marked potassium leakage from the otherwise intact cells. The possible role of membrane suli'hydryl groups in the development of certain types of hemolytic anemias,and in the maintenance of active transmembrane cation transport in the erythrocyte is discussed. - i - PREFACE AND ACKNOWLEDGE:MENTS The investigations described in this thesis represent a part of a larger project initiated to study the mechanism of hemolytic anemia in man. The first phase of this research was undertaken to investigate possible molecular changes occurring in the erythrocyte membrane in hemolytic anemia. The investigation was prompted by the observation of de Leeuw et al. (1) that drug-induced hemolysis, hitherto regarded as an inborn error of metabolism,-deficiency of a red cell enzyme, glucose-6-phosphate dehydrogenase (G6PD), may frequently occur in patients with no such deficiency. The investigation of this phenomenon has led to the study of the erythrocyte membrane, and specifically of the reactive sulfhydryl radicals in the erythrocyte membrane. In the course of this study, a technique has been developed for the quantitative titration of these important membrane constituents. Since early resulta have suggested alterations in the membrane sulfhydryl content of erythrocytes in certain conditions accompanied by increased red cell destruction, the scope of the investigation has been widened to a variety of associated hematological disorders. It is the development of this technique and the resulta obtained by its application that forma the subject of this thesis. The place of the presented findings in the long-range - ii - study of red cell hemolysis will be projected in the discussion of the findings. The more strictly clinical investigation of the patient material which was carried out simultaneously with this study will be omitted from the thesis. During the two years in which the work presented in this thesis was carried out, the writer was a Clinical Fellow of the Hematology Division, Department of Medicine, Royal Victoria Hospital. Throughout this period, advice and encouragement was readily offered by each and every member of the Division and enthusiastic cooperation was always forthcoming on the part of the hematology technicians. The author feels particularly indebted to Dr. Louis Lowenstein, whose guidance and direction in the philosophy and nature of medical research will far outlive the scope of this thesis, and to Dr. N.K.M. de Leeuw, whose help assisted the author in every phase of this study. Grateful thanks are also due to Dr. Bernard A. Cooper, who was always available with excellent ideas and assistance to solve the nunsolvable11 problems as they arose. The useful suggestions of Dr. Rhoda Blostein in the later phase of this study and in the preparation of the thesis is also gratefully acknow­ ledged. - iii - The technical assistance of Mrs. Ghislaine Houle in the laboratory work, Miss Barbara Heward in the preparation of the illustrations, and Miss Sylvia Sentheim in the typing of this thesis is acknowledged with deep appreciation. The research project was supported by a Grant from the Medical Research Council of Canada. iv TABLE OF CONTENTS Page PREFACE AND ACKNOWLEDGEMENTS • • • • • • • • • • • • • • • • • • • • • • i TABLE OF CONTENTS ••••••••••••••••••••••••••••••••• ii LIST OF FIGURES •••••••••·••••••••••••••••••••••••· ix LIST OF ABBREVIATIONS • • • • • • • • • • • • • • • • • • • • • • • • • • • • • x INTRODUCTION •.• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 1 CHAPTER I: HISTORICAL BACKGROUND • • • • • • • • • • • • • • • • • 5 PART I: SALIENT FEATURES OF SH GROUPS IN BIOLOGICAL MATERIAL • • • • • • • • • • • • • • • • • • • 5 1. The· .ro1e of SH groups in protein structure and function •••••••••••••••• 5 2. The reactivity of SH groups 1 • • • • • • • • • • • 7 3. Chemical reactions and inhibitions of .. SH groups •.•.•..••..•.............• PART II: RELATION OF SH GROUPS TO STRUCTURAL AND FUNCTIONAL COMPETENCE OF ERYTHROCYTES ••• 10 1. Correlation of red ce11 integrity and intrace1lular SH groups ••••••••••• 10 2. Correlation of red ce11 integrity and membrane SH groups •••••••••••••••••••• 11 a. The site of action of heavy metals •• 11 b. The hemolytic action of SH reagents. 12 c. The role of membrane SH groups in cellular integrity ••••••••••••••••• 13 d. The site of action of oxidative drugs . • • . • • • • . • • . • • . • . • . • 14 e. The role of membrane constituants in intracellular metabolism ••••••• 15 v Page CHAPTER II: EXPERIMENTAL • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 18 PART I: MA TERIALS AND METHODS • • • • • • • • • • • • • • • • • • • • là 1. Introduction to the methods of sulfhydryl determination ••••••••••••••••• là 2. Materials • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 20 A. Reagents • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 20 B. Substrate • • • • • • • • • • • • • • • • • • • • • • • • • • • • 22 3. P.reliminary experimenta for the application of Boyer's method of SH titration to intact erythrocytes •••••••••••••••••••••• 25 a) Titration of excess P.MB • • • • • • • • • • • • • • 26 b) Selection of PMB concentration and incubaJ-ion time •••••••••••••••••• 27 i. Incuba~on,of erythrocytes with various' concentrations of PMB • • • • • 2$ ii. The time course of PMB uptake by erythrocytes •••••••••••••••••• 29 4. Determination of intracellular GSH content in erythrocytes incubated with PMB •••••••• 30 5. The effect of leukocyte and reticulocyte content of red cell preparations on the PMB uptake of erythrocytes ••••••••••••••• 33 6. Resume of the technique used for the determination of erythrocyte membrane sulfhydryl content ••••••••••••••••••••••• 34 7. Other methods employed • • • • • • • • • • • • • • • • • • • 37 PART II: RESULTS • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 38 A. The reactive membrane sulfhydryl content of normal erythrocytes •••••••• 3à 1. The range and mean of normal membrane sulfhydryl content ...•....••••..............•..•.....•...• 38 2. Studies on ACD preserved blood • • • • • • • • • • • • • • • • • 39 vi Page PART II: (Cont'd) • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • B. Determination of erythrocyte membrane sulfhydry1 content in patients ••••••• 39 1. Erythrocyte membrane SR content in drug- induced hemo1ytic anemia •••••••••••••••••••••• 40 2. Membrane SR groups of G6PD-deficient erythrocytes •••••••••••••••••••············••• 42 3. The reactive membrane SH content in acquired hemo1ytic anemia •••••••••••••••••••••••••••••• 42 4. Erythrocyte membrane su1fhydry1 groups in hereditary spherocytosis •••••••••••••••••••••• 45 5. Erythrocyte membrane sulfhydry1 content in misce11aneous conditions with possible hemo1ytic component ···•·•••••••••••••••••••••• 45 6. Erythrocyte membrane su1fhydry1 content in iron deficiency anemia •••••••••••••••••••••••• 45 7. Erythrocyte membrane su1fhydry1 content in pernicious anemia ••••••••••••••••••••••••••••• 46 8. Erythrocyte membrane su1fhydry1 content in misce1laneous hemato1ogical conditions ••••••••• 46 9. The effect of azotemia on the erythrocyte membrane SH content ••••••••••••••••••••••••••• 47 10. The effect of su1fonamides on the erythrocyte membrane SH content ••••••••••••••••••·•······· 47 C. The time course of P.MB uptake in hemolytic anemia ••••••••••••••••• 48 D. The effect of FMB on the erythrocyte GSR 1eve1 ••••••••••••••••••••••••••• 49 E. The effect of PMB on cation transport in erythrocytes • • • • • • • • • • • 50 vii Page CHAPTER III: DISCUSSION • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • PART I: DISCUSSION OF THE TECHNIQUE OF ERYTHROCYTE MEMBRANE SULFHYDRYL GROUP DETERMINATION • • • • • • • • • • • • • • • • • • • • • • • • • • • • 51 1. The choice of intact cells as opposed to red cell ghosts •••••••••••••••••••••••••••••••• 51 2. The choice of reagent, concentration, and incubation time •••••••••••••••••••••••••••••••• 54 PART II: DISCUSSION OF THE RESULTS: THE REACTIVE SULFHYDRYL GROUPS OF
Load more

Recommended publications
  • Non-Commercial Use Only
    only use Non-commercial 14th International Conference on Thalassaemia and Other Haemoglobinopathies 16th TIF Conference for Patients and Parents 17-19 November 2017 • Grand Hotel Palace, Thessaloniki, Greece only use For thalassemia patients with chronic transfusional iron overload... Make a lasting impression with EXJADENon-commercial film-coated tablets The efficacy of deferasirox in a convenient once-daily film-coated tablet Please see your local Novartis representative for Full Product Information Reference: EXJADE® film-coated tablets [EU Summary of Product Characteristics]. Novartis; August 2017. Important note: Before prescribing, consult full prescribing information. iron after having achieved a satisfactory body iron level and therefore retreatment cannot be recommended. ♦ Maximum daily dose is 14 mg/kg body weight. ♦ In pediatric patients the Presentation: Dispersible tablets containing 125 mg, 250 mg or 500 mg of deferasirox. dosing should not exceed 7 mg/kg; closer monitoring of LIC and serum ferritin is essential Film-coated tablets containing 90 mg, 180 mg or 360 mg of deferasirox. to avoid overchelation; in addition to monthly serum ferritin assessments, LIC should be Indications: For the treatment of chronic iron overload due to frequent blood transfusions monitored every 3 months when serum ferritin is ≤800 micrograms/l. (≥7 ml/kg/month of packed red blood cells) in patients with beta-thalassemia major aged Dosage: Special population ♦ In moderate hepatic impairment (Child-Pugh B) dose should 6 years and older. ♦ Also indicated for the treatment of chronic iron overload due to blood not exceed 50% of the normal dose. Should not be used in severe hepatic impairment transfusions when deferoxamine therapy is contraindicated or inadequate in the following (Child-Pugh C).
    [Show full text]
  • 224 Subpart H—Hematology Kits and Packages
    § 864.7040 21 CFR Ch. I (4–1–02 Edition) Subpart H—Hematology Kits and the treatment of venous thrombosis or Packages pulmonary embolism by measuring the coagulation time of whole blood. § 864.7040 Adenosine triphosphate re- (b) Classification. Class II (perform- lease assay. ance standards). (a) Identification. An adenosine [45 FR 60611, Sept. 12, 1980] triphosphate release assay is a device that measures the release of adenosine § 864.7250 Erythropoietin assay. triphosphate (ATP) from platelets fol- (a) Identification. A erythropoietin lowing aggregation. This measurement assay is a device that measures the is made on platelet-rich plasma using a concentration of erythropoietin (an en- photometer and a luminescent firefly zyme that regulates the production of extract. Simultaneous measurements red blood cells) in serum or urine. This of platelet aggregation and ATP re- assay provides diagnostic information lease are used to evaluate platelet for the evaluation of erythrocytosis function disorders. (increased total red cell mass) and ane- (b) Classification. Class I (general mia. controls). (b) Classification. Class II. The special [45 FR 60609, Sept. 12, 1980] control for this device is FDA’s ‘‘Docu- ment for Special Controls for Erythro- § 864.7060 Antithrombin III assay. poietin Assay Premarket Notification (a) Identification. An antithrombin III (510(k)s).’’ assay is a device that is used to deter- [45 FR 60612, Sept. 12, 1980, as amended at 52 mine the plasma level of antithrombin FR 17733, May 11, 1987; 65 FR 17144, Mar. 31, III (a substance which acts with the 2000] anticoagulant heparin to prevent co- agulation). This determination is used § 864.7275 Euglobulin lysis time tests.
    [Show full text]
  • Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients
    European Journal of Environment and Public Health, 2017, 1(2), 06 ISSN: 2468-1997 Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients Nihad Rownak1, Shahin Akhter2, Monira Khatun3, Sohel Baksh4, Shafquat Rafiq5*, Mushfiqur Rahman6 1 Department of Physiology, University of Science & Technology Chittagong, BANGLADESH 2 Department of Physiology, Chittagong Medical College, Chittagong, BANGLADESH 3 Department of Physiology, Chattagram Maa O Shishu Hospital Medical College, Chittagong, BANGLADESH 4 Department of Physiology, Cox’s Bazar Medical College, BANGLADESH 5 Croydon University Hospital NHS Trust, UNITED KINGDOM 6 Department of Pediatric Surgery, Chittagong Medical College, Chittagong, BANGLADESH *Corresponding Author: [email protected] Citation: Rownak, N., Akhter, S., Khatun, M., Baksh, S., Rafiq, S., and Rahman, M. (2017). Study of Osmotic Fragility Status of Red Blood Cell in Type II Diabetes Mellitus Patients. European Journal of Environment and Public Health, 1(2), 06. https://doi.org/10.20897/ejeph/77094 Published: December 28, 2017 ABSTRACT Diabetes Mellitus (DM) is one of the most prevalent non-communicable diseases in the world. Cell membrane injury is an important mechanism for pathophysoilogical changes in DM. Osmotic fragility (OF) status of Red blood cell (RBC) in hyperglycemic patients is expected to be increased. This study was conducted in Chittagong medical college hospital and Chittagong Diabetic Hospital from January 2015 to December 2015. 100 newly diagnosed (duration ≤ 3 years) type II diabetes mellitus patients (Fasting blood glucose is ≥7 mmol/L) were selected as cases. Age, sex and BMI matched 100 healthy subjects were included as control. OF of RBC was measured by traditional method with a series of hypotonic solution of NaCl of different strength in twelve test tubes numbered serially.
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • 47 Effect of Gavage Treatment with Pulverised
    47 Nigerian Journal of Physiological Sciences 24 (1): 47-52 © Physiological Society of Nigeria, 2009 Available online/abstracted at http://www.biolineinternational.org.br/nps; www.ajol.info/journals.njps; www.cas.org EFFECT OF GAVAGE TREATMENT WITH PULVERISED GARCINIA KOLA SEEDS ON ERYTHROCYTE MEMBRANE INTEGRITY AND SELECTED HAEMATOLOGICAL INDICES IN MALE ALBINO WISTAR RATS A. A. AHUMIBE AND V. B. BRAIDE* Department of Pharmacology, Faculty of Basic Medical Science, College of Medical sciences, University of Calabar, PMB 1115, Calabar, Nigeria. E-mail: [email protected]. Tel.:+2348034048101 Summary: This study examines the effect of the whole seed of Garcinia kola (GKS ) on various blood parameters, in adult male albino rats. Five groups, of 6 animals per group, were treated by gavage with suspensions of graded concentrations of GKS daily for 5 weeks. The animals were then sacrificed and blood was obtained for estimation of the data herein presented. Packed red cell volume (PCV), hemoglobin concentration (Hb), and red blood cell count (RBC) showed significantly (P < 0.05, Student’s t-test) increased response to treatment with GKS; while the platelet and white blood cell (WBC) counts showed no corresponding increase with increasing GKS dosage. The mean red blood cell volume (MCV) and mean cell hemoglobin (MCH) levels decreased with increasing GKS dosage. Prothrombin time (PT) and activated partial thromboplastin time (APPT) were both prolonged with increased GKS dosage; while the serum lipids (cholesterol and triglycerides) decreased significantly (P< 0.05, Student’s t-test) with increased GKS dosage. Key Words: Garcinia kola; erythrocyte osmotic fragility; haematological parameters; serum cholesterol triglycerides Introduction One of many plant sources of therapeutic 2000); hypoglycaemic anti-diabetic activity (Iwu et ingredient among the people in West and Central al , 1990); bronchodilatation in man (Orie and Ekon Africa and some parts of Asia, is the seed plant 1993); antispasmodic effect on smooth muscle Garcinia kola Heckel (Guttiferae).
    [Show full text]
  • Hereditary Spherocytosis: Clinical Features
    Title Overview: Hereditary Hematological Disorders of red cell shape. Disorders Red cell Enzyme disorders Disorders of Hemoglobin Inherited bleeding disorders- platelet disorders, coagulation factor Anthea Greenway MBBS FRACP FRCPA Visiting Associate deficiencies Division of Pediatric Hematology-Oncology Duke University Health Service Inherited Thrombophilia Hereditary Disorders of red cell Disorders of red cell shape (cytoskeleton): cytoskeleton: • Mutations of 5 proteins connect cytoskeleton of red cell to red cell membrane • Hereditary Spherocytosis- sphere – Spectrin (composed of alpha, beta heterodimers) –Ankyrin • Hereditary Elliptocytosis-ellipse, elongated forms – Pallidin (band 4.2) – Band 4.1 (protein 4.1) • Hereditary Pyropoikilocytosis-bizarre red cell forms – Band 3 protein (the anion exchanger, AE1) – RhAG (the Rh-associated glycoprotein) Normal red blood cell- discoid, with membrane flexibility Hereditary Spherocytosis: Clinical features: • Most common hereditary hemolytic disorder (red cell • Neonatal jaundice- severe (phototherapy), +/- anaemia membrane) • Hemolytic anemia- moderate in 60-75% cases • Mutations of one of 5 genes (chromosome 8) for • Severe hemolytic anaemia in 5% (AR, parents ASx) cytoskeletal proteins, overall effect is spectrin • fatigue, jaundice, dark urine deficiency, severity dependant on spectrin deficiency • SplenomegalSplenomegaly • 200-300:million births, most common in Northern • Chronic complications- growth impairment, gallstones European countries • Often follows clinical course of affected
    [Show full text]
  • ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4
    ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants.
    [Show full text]
  • Sickle Cell: It's Your Choice
    Sickle Cell: It’s Your Choice What Does “Sickle Cell” Mean? Sickle is a type of hemoglobin. Hemoglobin is the substance that carries oxygen in the blood and gives blood its red color. A person’s hemoglobin type is not the same thing as blood type. The type of hemoglobin we have is determined by genes that we inherit from our parents. The majority of individuals have only the “normal” type of hemoglobin (A). However, there are a variety of other hemoglobin types. Sickle hemoglobin (S) is one of these types. There Are Two Forms of Sickle Cell. Sickle cell occurs in two forms. Sickle cell trait is not a disease; Sickle cell anemia (or sickle cell disease) is a disease. Sickle Cell Trait (or Sickle Trait) Sickle cell trait is found primarily in African Americans, people from areas around the Mediterranean Sea, and from islands in the Caribbean. Sickle cell trait occurs when a person inherits one sickle cell gene from one parent and one normal hemoglobin gene from the other parent. A person with sickle cell trait is healthy and usually is not aware that he or she has the sickle cell gene. A person who has sickle trait can pass it on to their children. If one parent has sickle cell trait and the other parent has the normal type of hemoglobin, there is a 50% (1 in 2) chance with EACH pregnancy that the baby will be born with sickle cell trait. When ONE parent has sickle cell trait, the child may inherit: • 50% chance for two normal hemoglobin genes (normal hemoglobin- AA), OR • 50% chance for one normal hemoglobin gene and one sickle cell gene (sickle cell trait- AS).
    [Show full text]
  • The Diagnostic Importance of Coagulation Parameters in Cattle Having Natural Theileriosis
    Polish Journal of Veterinary Sciences Vol. 20, No. 2 (2017), 369–376 DOI 10.1515/pjvs-2017-0045 Original article The diagnostic importance of coagulation parameters in cattle having natural theileriosis V. Gunes, A.C. Onmaz, I. Keles, K. Varol, G. Ekinci Erciyes University, Faculty of Veterinary Medicine, Department of Internal Medicine, Kayseri, 38100 Turkey Abstract The purpose of this study was to determine the diagnostic importance of coagulation parameters in cattle with natural theileriosis. Nine Holstein cross-breed cattle with theileriosis as infected group and 6 healthy Holstein cattle as control group were used in the present study. Mean fibrinogen level, thrombin time (TT), activated partial thromboplastin time (aPTT) and prothrombin time (PT) were not statistically different when control and infected groups compared, except for the D-dimer concen- tration. Quantitative D-dimer concentrations were determined by immune-turbidimetric assay. D-dimer values increased significantly (p<0.05) in infected group (631.55 ± 74.41 μg/L) compared to control group (370.00 ± 59.94 μg/L). D-dimer sensitivity and specificity were also determined at cut-off concentrations (372 μg/L). Sensitivity and specificity of D-dimer values were determined to be 88.89% and 83.33%, respectively. D-dimer is thought to be important indicator in the evaluation of the prognosis in theileriosis cases. Analysis of D-dimer values before and after treatment in controlled case studies were suggested in future studies to enlighten the issue. Key words: cattle, coagulopathy, D-dimer, haemolysis, theileriosis Introduction common. Haemolytic anaemia, icterus and death has been reported in the advanced stages of the disease Theileriosis is a protozoan disease transported to (Keles et al.
    [Show full text]
  • Sickle Cell Disease Brochure
    What is sickle cell trait? Who can have sickle cell disease and sickle cell trait? Sickle Cell Trait (AS) is an inherited condition which affects the hemoglobin in your red blood cells. » It is estimated that SCD affects 90,000 to 100,000 people in the United States, mainly Blacks or It is important to know if you have sickle cell trait. African Americans. All About: Sickle cell trait is inherited from your parents, » The disease occurs in about 1 of every 500 Black like hair or eye color. If one parent has sickle cell or African American births and in about 1 of every trait, there is a 50% (1 in 2) chance with each 36,000 Hispanic American births. Sickle Cell pregnancy of having a child with sickle cell trait. Sickle cell trait rarely causes any health problems. » SCD affects millions of people throughout the Some people may develop health problems under world and is particularly common among those certain conditions, such as: whose ancestors come from sub-Saharan Africa, Disease & regions in the Western Hemisphere (South » Dehydration – from not drinking enough water America, the Caribbean, and Central America), » Low oxygen – from over-exertion Saudi Arabia, India, and Mediterranean countries » High altitudes – from low oxygen levels such as Turkey, Greece, and Italy. Sickle Cell » About 1 of every 12 African Americans has sickle How do you know if you have sickle cell cell trait and about 1 of every 100 Hispanics has trait or disease? sickle cell trait. Trait » It is possible for a person of any race or nationality to have sickle cell trait.
    [Show full text]
  • The Formation of Methemoglobin and Sulfhemoglobin During Sulfanilamide Therapy
    THE FORMATION OF METHEMOGLOBIN AND SULFHEMOGLOBIN DURING SULFANILAMIDE THERAPY J. S. Harris, H. O. Michel J Clin Invest. 1939;18(5):507-519. https://doi.org/10.1172/JCI101064. Research Article Find the latest version: https://jci.me/101064/pdf THE FORMATION OF METHEMOGLOBIN AND SULFHEMOGLOBIN DURING SULFANILAMIDE THERAPY By J. S. HARRIS AND H. 0. MICHEL (From the Departments of Pediatrics and Biochemistry, Duke University School of Medicine, Durham) (Received for publication April 8, 1939) Cyanosis almost invariably follows the admin- during the administration of sulfanilamide. Wen- istration of therapeutic amounts of sulfanilamide del (10) found spectroscopic evidence of met- (1). This cyanosis is associated with and is due hemoglobin in every blood sample containing over to a change in the color of the blood. The dark- 4 mgm. per cent sulfanilamide. Evelyn and Mal- ening of the blood is present only in the red cells loy (11) have found that all patients receiving and therefore must be ascribed to one of two sulfanilamide show methemoglobinemia, although causes, a change in the hemoglobin itself or a the intensity is usually very slight. Finally Hart- staining of the red cells with some product formed mann, Perley, and Barnett (12) found cyanosis during the metabolism of sulfanilamide. It is the associated with methemoglobinemia in almost ev- purpose of this paper to assay quantitatively the ery patient receiving over 0.1 gram sulfanilamide effect of sulfanilamide upon the first of these fac- per kilogram of body weight per day. They be- tors-that is, upon the formation of abnormal lieved that the intensity of the methemoglobinemia heme pigments.
    [Show full text]
  • The Role of Nonhemoglobin Proteins and Reduced Glutathione in the Protection of Hemoglobin from Oxidation in Vitro
    The Role of Nonhemoglobin Proteins and Reduced Glutathione in the Protection of Hemoglobin from Oxidation In Vitro A. S. Hill Jr., … , G. E. Cartwright, M. M. Wintrobe J Clin Invest. 1964;43(1):17-26. https://doi.org/10.1172/JCI104889. Research Article Find the latest version: https://jci.me/104889/pdf Journal of Clinical Investigatiox Vol. 43, No. 1, 1964 The Role of Nonhemoglobin Proteins and Reduced Glutathione in the Protection of Hemoglobin from Oxidation In Vitro * A. S. HILL, JR., A. HAUT, G. E. CARTWRIGHT, AND M. M. WINTROBE (From the Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah) A deficiency of reduced glutathione in erythro- human erythrocytes by Allen and Jandl (10) led cytes of freshly shed blood (1-4) or in erythro- these authors to conclude that GSH per se pro- cytes exposed to certain chemical compounds (5) tects hemoglobin from oxidation and that no ad- has been associated with shorter red cell survival ditional factors are required; conversely, Szein- and, in most cases, with the accumulation of oxi- berg and Marks (11) found that GSH affords no dation products of hemoglobin, including methe- protection to human hemoglobin against oxidative moglobin, sulfhemoglobin, and Heinz bodies. changes. The earlier report of Foulkes and Studies of "primaquine-sensitive" hemolytic dis- Lemberg (12) that GSH might oxidize hemo- ease have emphasized as a characteristic feature globin, along with the studies by Szeinberg and an "unstable" reduced glutathione (GSH) in the Marks (11) and Allen and Jandl (10), casts red cells, attributed to limited availability of re- doubt on the applicability to humans of the con- duced TPN (TPNH), the result, in turn, of a cept (13, 14), based on studies of rat blood (7, deficiency of the enzyme, glucose-6-phosphate 8), that an adequate amount of reduced glutathi- dehydrogenase - (G6PD).
    [Show full text]